Literature DB >> 16127039

Absolute bioavailability and pharmacokinetics of linezolid in hospitalized patients given enteral feedings.

Paul Beringer1, Megan Nguyen, Nils Hoem, Stan Louie, Mark Gill, Michael Gurevitch, Annie Wong-Beringer.   

Abstract

Linezolid is a new antimicrobial agent effective against drug-resistant gram-positive pathogens which are common causes of infections in hospitalized patients. Many such patients rely on the intravenous or enteral route for nutrition and drug administration. Therefore, the bioavailability of linezolid administered enterally in the presence of enteral feedings in hospitalized patients was examined. Eighteen subjects were assessed in a randomized single-dose crossover study; 12 received continuous enteral feedings, while 6 did not (controls). Both groups received linezolid 600 mg intravenously and orally (control) or enterally, with the alternate route of administration separated by a 24-h washout period. Pharmacokinetic parameters derived from noncompartmental and compartmental analysis incorporating linear and nonlinear elimination pathways were compared between groups: F, Ka, Vs, K23, K32, Vmax, Km, and K20 (bioavailability, absorption rate constant, volume of central compartment normalized to body weight, intercompartmental rate constants, maximum velocity, Michaelis-Menten constant, and elimination rate constant, respectively). Pharmacokinetic (PK) data were available from 17 patients. The linezolid oral suspension was rapidly and completely absorbed by either the oral or enteral route of administration. Bioavailability was unaltered in the presence of enteral feedings. PK estimates remain similar regardless of the model applied. At the therapeutic dose used, only slight nonlinearity in elimination was observed. A linezolid oral suspension may be administered via the enteral route to hospitalized patients without compromise in its excellent bioavailability and rapid rate of absorption. Compartmental pharmacokinetic analysis offers a more flexible study application, since bioavailability (F) can be estimated directly with intermixed intravenous/oral doses without a need for a washout period.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16127039      PMCID: PMC1195442          DOI: 10.1128/AAC.49.9.3676-3681.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Determination of linezolid in human serum and urine by high-performance liquid chromatography.

Authors:  K Borner; E Borner; H Lode
Journal:  Int J Antimicrob Agents       Date:  2001-09       Impact factor: 5.283

2.  Age and sex effects on the pharmacokinetics of linezolid.

Authors:  T Lasher Sisson; G L Jungbluth; N K Hopkins
Journal:  Eur J Clin Pharmacol       Date:  2002-01       Impact factor: 2.953

3.  Linezolid absolute bioavailability and the effect of food on oral bioavailability.

Authors:  I R Welshman; T A Sisson; G L Jungbluth; D J Stalker; N K Hopkins
Journal:  Biopharm Drug Dispos       Date:  2001-04       Impact factor: 1.627

4.  Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers.

Authors:  Dennis J Stalker; Gail L Jungbluth; Nancy K Hopkins; Donald H Batts
Journal:  J Antimicrob Chemother       Date:  2003-03-28       Impact factor: 5.790

5.  A simple, isocratic high-performance liquid chromatography assay for linezolid in human serum.

Authors:  C M Tobin; J Sunderland; L O White; A P MacGowan
Journal:  J Antimicrob Chemother       Date:  2001-11       Impact factor: 5.790

Review 6.  Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections.

Authors:  Alasdair P MacGowan
Journal:  J Antimicrob Chemother       Date:  2003-05       Impact factor: 5.790

7.  Pharmacokinetics and absolute bioavailability of ciprofloxacin administered through a nasogastric tube with continuous enteral feeding to critically ill patients.

Authors:  O Mimoz; V Binter; A Jacolot; A Edouard; M Tod; O Petitjean; K Samii
Journal:  Intensive Care Med       Date:  1998-10       Impact factor: 17.440

8.  Population pharmacokinetics of linezolid in patients treated in a compassionate-use program.

Authors:  Alison K Meagher; Alan Forrest; Craig R Rayner; Mary C Birmingham; Jerome J Schentag
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

Review 9.  Linezolid: the first oxazolidinone antimicrobial.

Authors:  Robert C Moellering
Journal:  Ann Intern Med       Date:  2003-01-21       Impact factor: 25.391

Review 10.  The changing epidemiology of Staphylococcus aureus?

Authors:  H F Chambers
Journal:  Emerg Infect Dis       Date:  2001 Mar-Apr       Impact factor: 6.883

View more
  16 in total

1.  Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis.

Authors:  Rebecca A Keel; Andre Schaeftlein; Charlotte Kloft; J Samuel Pope; R Frederic Knauft; Marianne Muhlebach; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2011-04-25       Impact factor: 5.191

2.  Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients.

Authors:  Yasuhiro Tsuji; Nicholas H G Holford; Hidefumi Kasai; Chika Ogami; Young-A Heo; Yoshitsugu Higashi; Akiko Mizoguchi; Hideto To; Yoshihiro Yamamoto
Journal:  Br J Clin Pharmacol       Date:  2017-03-31       Impact factor: 4.335

3.  Bacterial meningitis in older adults.

Authors:  Diedre Hofinger; Larry E Davis
Journal:  Curr Treat Options Neurol       Date:  2013-08       Impact factor: 3.598

4.  Repurposing niclosamide for intestinal decolonization of vancomycin-resistant enterococci.

Authors:  Haroon Mohammad; Ahmed AbdelKhalek; Nader S Abutaleb; Mohamed N Seleem
Journal:  Int J Antimicrob Agents       Date:  2018-02-09       Impact factor: 5.283

5.  Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients.

Authors:  Tomohiro Sasaki; Hiroshi Takane; Katsuhiro Ogawa; Sayaka Isagawa; Takeshi Hirota; Shun Higuchi; Toshinobu Horii; Kenji Otsubo; Ichiro Ieiri
Journal:  Antimicrob Agents Chemother       Date:  2011-02-28       Impact factor: 5.191

6.  Population Pharmacokinetics and Dosage Optimization of Linezolid in Critically Ill Pediatric Patients.

Authors:  Mei Yang; Libo Zhao; Xiaohui Wang; Chen Sun; Hengmiao Gao; Xiaoling Wang; Suyun Qian
Journal:  Antimicrob Agents Chemother       Date:  2021-02-08       Impact factor: 5.191

7.  In Vivo Antibacterial Activity of Acetazolamide.

Authors:  Nader S Abutaleb; Ahmed Elkashif; Daniel P Flaherty; Mohamed N Seleem
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

8.  Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients.

Authors:  Iris K Minichmayr; André Schaeftlein; Joseph L Kuti; Markus Zeitlinger; Charlotte Kloft
Journal:  Clin Pharmacokinet       Date:  2017-06       Impact factor: 6.447

9.  Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults.

Authors:  Amira A Bhalodi; Pavlos K Papasavas; Darren S Tishler; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

10.  Applicability of a Single Time Point Strategy for the Prediction of Area Under the Concentration Curve of Linezolid in Patients: Superiority of Ctrough- over Cmax-Derived Linear Regression Models.

Authors:  Nuggehally R Srinivas; Muzeeb Syed
Journal:  Drugs R D       Date:  2016-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.